| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/31/2002 | CN1360939A Nanometer eyesight-improving and health-clearing medicine and its prepn |
| 07/31/2002 | CN1360936A Nanometer Yunnan Baiyao medicine and its prepn |
| 07/31/2002 | CN1360930A Nanometer traumatic injury-treating medicine and its prepn |
| 07/31/2002 | CN1360923A Chinese herb medicine composition with kidney-reinforcing and blood circulation-promoting functions |
| 07/31/2002 | CN1360913A Nanometer Xiaojing medicine and its prepn |
| 07/31/2002 | CN1360892A Dry mixed suspension of Meptin and pseudoephe and its prepn |
| 07/31/2002 | CN1088456C Substituted oxazolidine calpain and/or cathepsin B inhibitors |
| 07/31/2002 | CN1088375C Medicinal tea for invigorating kidney and replenishing vital essence |
| 07/31/2002 | CN1088372C Method for producing aloe tablets |
| 07/31/2002 | CN1088369C Moxibustion liquid and its producing method |
| 07/31/2002 | CN1088368C Baiyesan-medicinal powder |
| 07/31/2002 | CN1088361C Combined use of diclofenac and tribenoside to treat osteoarthritis |
| 07/31/2002 | CN1088359C Medicine for curing cerebrovascular disturbance with psychonosema |
| 07/31/2002 | CA2369462A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of pde4 isozymes |
| 07/30/2002 | US6426413 Inhibitors of caspases |
| 07/30/2002 | US6426402 Respiratory system disorders; rheumatic diseases |
| 07/30/2002 | US6426401 Pharmaceutical composition containing an inhibitor of immunoglobulin-receptor interaction |
| 07/30/2002 | US6426369 Oxethazaine as antimicrobial agent |
| 07/30/2002 | US6426365 CETP activity inhibitors |
| 07/30/2002 | US6426358 Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
| 07/30/2002 | US6426357 Antagonists of follicle stimulating hormone activity |
| 07/30/2002 | US6426353 α v integrin receptor antagonists |
| 07/30/2002 | US6426350 Alpha-2 adrenoceptor antagonists; use treating nervous system disorders |
| 07/30/2002 | US6426348 For therapy of inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (ra), multiple sclerosis, (ms), asthma, and inflammatory bowel disease (i bd) |
| 07/30/2002 | US6426347 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands |
| 07/30/2002 | US6426345 Phosphodiesterase inhibitors; antiinflammatory agents |
| 07/30/2002 | US6426344 Aryl and heteroaryl substituted indolealkanoic acids |
| 07/30/2002 | US6426341 Treatment for diabetic complications |
| 07/30/2002 | US6426208 Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| 07/30/2002 | US6426199 Isolated, purified nucleic acid detecting or isolating mutant forms of the dna molecules. |
| 07/30/2002 | US6426100 Method for improving bone modeling and chondrocyte functioning in growing canines |
| 07/30/2002 | US6426094 Method of enhancing the efficacy of anti-tumor agents |
| 07/30/2002 | US6426071 Administering protein c |
| 07/30/2002 | US6426059 Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes |
| 07/30/2002 | CA2344707C N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives |
| 07/30/2002 | CA2268433C Improved interferon polymer conjugates |
| 07/30/2002 | CA2226293C Hcv ns3 protein fragments having helicase activity and improved solubility |
| 07/30/2002 | CA2160543C Methods and compositions for delaying or preventing the onset of autoimmune disease |
| 07/30/2002 | CA2104461C Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same |
| 07/26/2002 | CA2369264A1 Method of treating certain cancers using an estrogen agonist/antagonist |
| 07/25/2002 | WO2002058323A2 Method for identifying modulators of bace |
| 07/25/2002 | WO2002057492A1 Methods and compositions for detecting polynucleotide duplex damage |
| 07/25/2002 | WO2002057489A2 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression |
| 07/25/2002 | WO2002057484A2 Method and test system for identifying substances which protect nerve cells |
| 07/25/2002 | WO2002057474A2 Processes for enhanced production of pantothenate |
| 07/25/2002 | WO2002057473A1 Method for inhibiting vegf and epo gene expression by quercetin |
| 07/25/2002 | WO2002057460A2 Polynucleotides encoding human phosphatases |
| 07/25/2002 | WO2002057449A1 Novel gene tifa |
| 07/25/2002 | WO2002057444A1 Human apoptosis-associated genes and human apoptosis-associated proteins produced thereby |
| 07/25/2002 | WO2002057441A1 Novel g protein-coupled receptor protein and dna thereof |
| 07/25/2002 | WO2002057425A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 07/25/2002 | WO2002057415A2 Method for altering cell fate |
| 07/25/2002 | WO2002057413A2 Peptides for activation and inhibition of delta pkc |
| 07/25/2002 | WO2002057409A2 Antisense modulation of src-2 expression |
| 07/25/2002 | WO2002057306A1 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
| 07/25/2002 | WO2002057300A1 Regulated activation of cell-membrane receptors by metal-chelating agonists |
| 07/25/2002 | WO2002057298A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | WO2002057287A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 07/25/2002 | WO2002057285A1 Fullerene derivative and composition comprising the same |
| 07/25/2002 | WO2002057270A1 Inhibitors of cruzipain and other cysteine proteases |
| 07/25/2002 | WO2002057267A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | WO2002057260A1 Compounds for use in the treatment of skin conditions |
| 07/25/2002 | WO2002057259A2 Pyrazole compounds useful as protein kinase inhibitors |
| 07/25/2002 | WO2002057256A1 Piperazinylcarbonylquinolines and -isoquinolines |
| 07/25/2002 | WO2002057252A2 Heterocyclic sulfonamide inhibitors of beta amyloid production |
| 07/25/2002 | WO2002057250A1 Tetrahydropyran derivatives as neurokinin receptor antagonists |
| 07/25/2002 | WO2002057249A1 Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases |
| 07/25/2002 | WO2002057248A2 Inhibitors of cruzipain and other cysteine proteases |
| 07/25/2002 | WO2002057242A2 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | WO2002057231A2 Benz(g) indoles and their use as spla2 inhibitors |
| 07/25/2002 | WO2002057230A1 Il-8 receptor antagonists |
| 07/25/2002 | WO2002057222A2 Thiol-based naaladase inhibitors |
| 07/25/2002 | WO2002057219A1 Novel 1,2-diphenylethene derivatives for treatment of immune diseases |
| 07/25/2002 | WO2002057218A1 Alanine 2,6-dialkoxyphenyl ester derivatives as hypnotics |
| 07/25/2002 | WO2002057211A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | WO2002056916A2 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 07/25/2002 | WO2002056912A2 Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent |
| 07/25/2002 | WO2002056911A1 Transplantation rejection inhibitors |
| 07/25/2002 | WO2002056902A2 Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
| 07/25/2002 | WO2002056894A1 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent |
| 07/25/2002 | WO2002056891A1 Regulation of glucocorticoid concentration |
| 07/25/2002 | WO2002056890A1 Novel method and compositions for local treatment of meniere's disease, tinnitus and/or hearing loss |
| 07/25/2002 | WO2002056887A1 New combination of active ingredients containing alfuzosine and apomorphine |
| 07/25/2002 | WO2002056880A1 Triphenylmethane kinesin inhibitors |
| 07/25/2002 | WO2002056878A2 Pharmaceutical composition having reduced tendency for drug crystallization |
| 07/25/2002 | WO2002056875A2 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 07/25/2002 | WO2002056874A2 Lipid-based nitric oxide donors |
| 07/25/2002 | WO2002056790A2 Delivery of therapeutic capable agents |
| 07/25/2002 | WO2002056755A2 Method for treating cancer |
| 07/25/2002 | WO2002056753A2 P27 prevents cellular migration |
| 07/25/2002 | WO2002056745A2 Method of treating parkinson's disease |
| 07/25/2002 | WO2002056692A1 Methods for modulating tumor growth and metastasis |
| 07/25/2002 | WO2002043663A3 Tetrapartate prodrugs |
| 07/25/2002 | WO2002043652A3 Anti-proliferative drugs |
| 07/25/2002 | WO2002042268A3 Ep4 receptor selective agonists in the treatment of osteoporosis |
| 07/25/2002 | WO2002040041A3 Orally ingestible preparation of mistletoe lectins and method |
| 07/25/2002 | WO2002039988A3 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 07/25/2002 | WO2002032901A3 Bridged piperazine derivatives |
| 07/25/2002 | WO2002032874A3 Substituted heterocyclic compounds for treating multidrug resistance |
| 07/25/2002 | WO2002032422A3 Ep4 receptor inhibitors to treat rheumatoid arthritis |